Effects of ezetimibe on postprandial hyperlipidemia.

Effects of ezetimibe on postprandial hyperlipidemia. - Effects of ezetimibe on postprandial hyperlipidemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003392

Enrollment

Registered

2010-04-01

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

ezetimibe monotherapy TLC(diet &amp

exercise)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The levels of TC are 220mg/dL and more or TG are150mg/dL and more.

Exclusion criteria

Exclusion criteria: 1)TG > 400mg/dL 2)ATL levels > 2 times the upper limit of normal 3)Serum Cr levels > 3.0mg/dL 4) Patients with secondary hyperlipidemia or drug-associated hyperlipidemia 5)Homozygous familial hypercholesterolemia 6)Patients with a history of unstable angina, MI, CABG or stroke within 3 months of study entry 7) Patients who are pregnant or nursing mothers, patients who may be pregnant, or patients who want to become pregnant during participation in the study. 8) Patients with a history of hypersensitivity to any ingredient of ezetimibe tablets 9) Other patients deemed not appropriate for study entry by the investigator.

Design outcomes

Primary

Measure	Time frame
The change of postprandial liipd levels (TG, apoB48, RLP-C)	—

Countries

Japan

Contacts

Public ContactHirotoshi Ohmura

Juntendo University, School of Medicine Cardiology

hohmura@juntendo.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026